Dehydroepiandrosterone Disease Interactions
There are 3 disease interactions with dehydroepiandrosterone.
Estrogens (applies to dehydroepiandrosterone) abnormal vaginal bleeding
Major Potential Hazard, Moderate plausibility. Applicable conditions: Abnormal Uterine Bleeding
The use of estrogens is contraindicated in patients with undiagnosed, abnormal vaginal bleeding. Prolonged (> 1 year), unopposed estrogen use (i.e. estrogen without concomitant progestin therapy) has been associated with a significant, dose-related risk of endometrial carcinoma. The risk may be offset substantially by the addition of a progestin but may not be completely abolished. Prior to initiating estrogen therapy, appropriate diagnostic tests should be performed in patients with abnormal vaginal bleeding to rule out endometrial malignancy. The same applies if recurrent or persistent bleeding develops during estrogen therapy.
Estrogens (applies to dehydroepiandrosterone) carcinomas (estrogenic)
Major Potential Hazard, Moderate plausibility. Applicable conditions: Neoplasia -- Estrogen Dependent
The use of estrogens is generally contraindicated in patients with known or suspected estrogen-dependent neoplasia such as breast and endometrial cancer, since it may stimulate tumor proliferation. High dosages of estrogens may be used for the palliative treatment of inoperable, metastatic breast cancer, but only in appropriately selected men and postmenopausal women.
Estrogens (applies to dehydroepiandrosterone) thromboembolism/cardiovascular
Major Potential Hazard, Moderate plausibility. Applicable conditions: Migraine, Ischemic Heart Disease, Cerebral Vascular Disorder, Thrombotic/Thromboembolic Disorder, History - Thrombotic/Thromboembolic Disorder
The use of estrogens is considered by manufacturers and some authorities to be contraindicated in patients with active thrombotic, thromboembolic, or thrombophilic disorders. The use of estrogen-containing oral contraceptives is additionally deemed contraindicated in patients with a history of such disorders and/or current cerebrovascular or coronary artery disease. Females with a history of migraines with aura are at an increased risk for stroke and this stroke risk may be further increased in females who have migraines with aura with use of combination oral contraceptives. Hypercoagulability and changes in various clotting factors and blood components have been observed in women receiving estrogen therapy. Known preexisting risk factors for increased thromboembolic or cardiovascular events include smoking, especially over age of 35; hypertension; hyperlipidemia; obesity; diabetes; age over 40; and lupus. Therapy with estrogens should be administered cautiously in the lowest effective dosage and only after careful consideration of risks and benefits. Estrogens should be avoided in patients with a history of thrombotic and thromboembolic disorders associated with estrogen use, except when used in the treatment of metastatic breast or prostatic malignancy.
Switch to professional interaction data
Dehydroepiandrosterone drug interactions
There are 188 drug interactions with dehydroepiandrosterone.
More about dehydroepiandrosterone
- dehydroepiandrosterone consumer information
- Check interactions
- Compare alternatives
- Reviews (118)
- Side effects
- Dosage information
- During pregnancy
- Drug class: miscellaneous sex hormones
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.